Project Grant R37CA304560
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $518K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- Federal Grant Award Summary The University of Utah received a $635,581 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year award supports the development of syngeneic, mutation-driven melanoma models in autoimmune-prone mice to advance understanding of immune checkpoint inhibitor (ICI) therapeutic efficacy and safety. The research addresses a critical gap in preclinical...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Utah $183,600 under the Cancer Research Manpower program (CFDA 93.398) to conduct research addressing immunotherapy resistance in cancer patients. The three-year project, initiated September 1, 2025 and concluding August 31, 2028, focuses on reprogramming myeloid cells through JAK (Janus kinase) inhibition to enhance checkpoint blockade therapy efficacy. The research examines the combination of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $126,933 to the University of Utah under the Cancer Research Manpower program (CFDA 93.398) for a two-year project period commencing May 1, 2026. This Project Grant supports research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The award funds investigator-initiated research examining how androgens enhance immune responses to improve immunotherapy...
- Federal Project Grant Award Summary The University of Utah's Office of Sponsored Projects received a $201,960 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 11, 2025, with completion targeted for August 31, 2028. This award supports investigator-initiated biomedical research training and cancer research development activities focused on understanding immune-mediated mechanisms in colorectal cancer (CRC)...
- Federal Project Grant Award Summary The University of Utah's Office of Sponsored Projects received a $634,900 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year award funds preclinical and translational research investigating the combined effects of Focal Adhesion Kinase (FAK) inhibition with Mitogen-Activated Protein Kinase (MAPK) blockade as a therapeutic...
- Federal Project Grant Award Summary The University of Utah received a $154,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. This technology-oriented project will develop and validate a novel genetic mouse model system for pancreatic ductal adenocarcinoma (PDAC) research. The primary deliverable is the creation and functional validation of a "FLP-OUT" mouse model using a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award funds fundamental research investigating the KEAP1-NRF2 redox sensing pathway's role in regulating CD8 T cell adaptation and stemness in the context of cancer and chronic infection. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Colorado-Denver $584,510 under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, with completion scheduled for August 31, 2029. This Project Grant supports the continued development and implementation of advanced spatial transcriptomics and proteomics technologies within the Human Immune Monitoring Shared Resource (HIMSR), a core facility of the University of Colorado Cancer Center...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...